Cell Reprogramming Market Size, Share & Trends Analysis Report By Technology (Sendai Virus-based, mRNA Reprogramming), By Application (Research, Therapeutic), By End-use, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global cell reprogramming market size was valued at USD 311.66 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 8.1% from 2022 to 2030. Stem cells are studied and developed into treatments for a variety of ailments using cell reprogramming methods, such as a method to replenish cells damaged by disease. These cells are created from somatic cells, such as blood or skin cells, which have undergone genetic reprogramming to resemble embryonic stem cells to produce an endless source of a wide variety of human cells for therapeutic purposes. Several factors, such as advances in stem cell biology & regenerative medicine for providing a viable treatment and increasing applicability of cell reprogramming in the healthcare sector, are also contributing to the industry growth.

The WHO estimates that the prevalence of chronic disease was 57% in 2020. Increasing adoption of stem cell therapies for various diseases is anticipated to positively impact industry growth. For instance, currently, each year in Europe, blood stem cells are used to treat about 26,000 patients. Moreover, the increasing demand for reprogramming for stem cell or cell-based drugs is predicted to drive the market during the forecast period. The outbreak of the COVID-19 pandemic led to an increase in the use of cell reprogramming methods for the production of personalized drugs. For instance, in March 2021, an important stage in cell reprogramming enabling safe drug screening and other tailored illness therapy has been identified and described by the UCLA bioengineers and associates, who also play a significant role in the development of new medications and personalized medicine.

Furthermore, researchers are engaged in the development of novel medications and treatments to fight this pandemic. In this situation, iPSCs are effective research resources for creating normal, relevant cell types for SARS-CoV-2. In addition, the creation of physiologically-specific human-cell models that can mimic the pathophysiology of COVID-19 using iPSCs is crucial for facilitating drug testing and has sparked the attention of pharmaceutical businesses in delivering medicines swiftly by taking advantage of cell reprogramming technology. The increasing investments from governments and private players in this space are anticipated to have a substantial impact on the industry expansion.

For instance, in May 2019, Mogrify, a U.K.-based company, increased its Series A financing by an additional USD15.61 million. Mogrify specializes in creating therapeutics and reprogramming human cells to combat retinal degeneration, a type of blindness. Moreover, the pharmaceutical industry is projected to use the iPSC approach widely to generate effective cell sources, such as iPSC-derived functional cells, to enable drug screening and toxicity assessment, which will increase the demand for cell reprogramming technology. New players are entering the market with sophisticated technologies to meet the growing demand and capture untapped avenues of the industry.

For instance, in January 2020, Allele Biotechnology & Pharmaceuticals, Inc. and Astellas Pharma Inc., entered into a licensing agreement through its subsidiary Astellas Institute for Regenerative Medicine (AIRM) to increase the focus on expanding its core competency in reprogramming somatic cells into iPSCs. Allele’s researchers and the cGMP team are also dedicated to establishing and verifying cell assays for product quality control, genomic analysis workflows, closed-system technology for reprogramming, and machine learning in iPSC-related sectors to fully utilize the unmatched potential of iPSC. Such endeavors by biotech corporations are anticipated to provide the development of induced pluripotent stem cells a strong push and further boost the industry growth.

Technology Insights

The mRNA technology segment accounted for the highest share of more than 36.10% of the overall revenue in 2021. This technology is easy to use and offers a quick, secure, & effective way to create human iPS cells of the highest quality from somatic tissue. It also provides a reprogramming efficiency of better than 1% and an advantage when working with difficult-to-reprogram samples. For instance, according to an article published in February 2021, synthetic mRNA cell reprogramming is an accurate and reliable method to generate human iPSCs. Sendai virus-based reprogramming is also anticipated to expand at a significant growth rate during the projected period.

As it generates cell reprogramming at a steady rate and has technological superiorities over other techniques, it has a high adoption rate among patients and is widely used in clinical studies of gene therapy and vaccine delivery. For instance, in May 2018, a Sendai virus reprogrammed system was developed by the International Society of Cell and Gene Therapy for use in clinical and translational studies. In addition, techniques were developed using the Sendai antibody for the detection and removal of undesirable cells, as well as qPCR-based SeV quantification to ensure that the clones produced were footprint-free. Furthermore, increased chronic disease incidences continued technological advancements in reprogramming technology, and rising awareness in emerging nations are primary growth drivers.

Application Insights

On the basis of applications, the global industry has been further bifurcated into research and therapeutic. The research application segment dominated the industry in 2021 and accounted for the highest share of more than 80.35% of the overall revenue. One of the main drivers fueling segment growth is an ongoing research area in the field of cell reprogramming with the help of stem cells. Governments as well as other private groups are funding considerable stem cell research studies, which is pushing the industry participants to carve their niches in the global sector by treating a range of chronic conditions.

For instance, 64% of Americans support federal financing for chronic disease research using stem cells from human embryos. Thus, research efforts are anticipated to supplement the segment growth. Cell reprogramming has already opened up incredible possibilities for therapeutics, such as new drug treatments that inhibit degenerative changes or encourage stem or progenitor cells to distinguish the difference in the affected lineage in a particular condition, which are both possible as a result of reprogramming studies. Some degenerative disorders might also be treatable with cell transplantation. The speed and breadth of these developments are promoting segment growth.

End-use Insights

On the basis of end-uses, the global industry has been further categorized into research & academic institutes, biotechnology & pharmaceutical companies, and hospitals & clinics. The research & academic institutes segment dominated the global industry in 2021 and accounted for the highest share of more than 36.10% of the overall revenue. Cell reprogramming has recently been transferred from the lab to the clinic by researchers. In numerous clinical and academic research projects, including those involving regenerative medicine, disease modeling, and medication toxicity/drug discovery studies, cell reprogramming has been used.

Furthermore, the clinical application of this technology is greatly facilitated by the use of cell reprogramming in regenerative medicine. This is linked to the growing research efforts examining the effectiveness and safety of cell reprogramming, which have helped the category flourish. The segment is also expected to be driven by an increase in the number of strategic efforts for research and method for innovative products from cell reprogramming. For instance, The California Institute for Regenerative Medicine has encouraged various research groups to contribute funds for cellular reprogramming’s transition to therapeutic applications and a clinical focus.

Regional Insights

North America dominated the industry in 2021 and accounted for the largest share of 35.14% of the total revenue. The high share can be attributed to the ongoing iPSC technology advancements and the availability of functional cells for pre-clinical drug testing. High throughput drug toxicity analysis and expanding knowledge of the iPSC platform both contribute to the region’s expansion. In the U.S., activities in medical research have increased as a result of the growing need for innovative treatment options. One of the main areas of attention is stem cell research, hence the requirement for cell reprogramming has been favored by this expanded study.

For instance, in April 2022, to help the iPSC reprogramming industry expansion, Ncardia announced the opening of a new company named Cellistic. Its emphasis and proficiency in differentiation, iPSC reprogramming, and other areas aid in market growth. Asia Pacific is estimated to be the fastest-growing region due to the improvements in production & the efficiency of the therapy landscape. The COVID-19 pandemic has further fueled the market growth in Asia Pacific on account of the large patient population base and there are currently no effective treatments for the infection, particularly in severe cases.

Genomic variants are the main cause of a wide variety of variability in the clinical symptoms of patients. Consequently, it is acknowledged that individualized care can effectively address these symptoms. As a result, the region is growing due to the increased adoption of cell reprogramming technologies. In addition, the expansion of medical development frameworks and better healthcare systems in developing nations like Australia and India has set the Asia Pacific region up to see lucrative growth over the period.

Key Companies & Market Share Insights

Key players are implementing various strategies including partnerships through mergers and acquisitions, geographical expansion, and strategic collaborations to expand their industry presence. For instance, in April 2021, Tidal Therapeutics was acquired by Sanofi. In addition, Sanofi’s research capabilities in immuno-oncology and inflammatory disorders will be enhanced by the new technology platform, which is also probably broadly applicable to other disease areas. Some of the key players in the global cell reprogramming market include:

• Allele Biotechnology

• ALSTEM

• Applied Biological Materials

• Axol Bioscience

• Creative Bioarray

• DefiniGEN

• Fujifilm Cellular Dynamics

• Lonza

• Mogrify

• REPROCELL

• Stemnovate

• Thermo Fisher Scientific

Cell Reprogramming Market Report Scope

Global Cell Reprogramming Market Segmentation 

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global cell reprogramming market report on the basis of technology, application, end-use, and region:

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Sendai virus-based Reprogramming

  • mRNA Reprogramming

  • Episomal Reprogramming

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Research

  • Therapeutic

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Research & Academic Institutes

  • Biotechnology & Pharmaceutical Companies

  • Hospitals & Clinics

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa

    • Saudi Arabia